Tonix Pharmaceuticals

On Thursday, January 29 at 2:30 PM, Gregory Sullivan, MD, Chief Medical Officer of Tonix Pharmaceuticals, will discuss the recently FDA-approved medicine, TONMYA, a centrally acting, non-opioid analgesic for the treatment of fibromyalgia, at the Non-Opioid Pain Therapeutics Summit in Boston, highlighting key learnings from Phase 3 studies, and the role of targeting non-refreshing sleep to address core symptoms. #Fibromyalgia #NonOpioidPain #PainTherapeutics #Biotech #ClinicalResearch

A productive week in San Francisco for the Tonix Pharmaceuticals team, engaging with investors and biotech leaders and sharing the Tonix story. We’re heading into 2026 energized, focused, and confident in what’s ahead! #Tonix #Biotech #Biopharma #HealthcareInnovation #JPMHC2026

Regulatory modernization will be a defining factor for biopharma in 2026. In PharmaVoice’s Crystal Ball feature, Tonix Pharmaceuticals CEO Dr. Seth Lederman discusses how smarter review pathways and real-world evidence can help move meaningful therapies forward more efficiently. Thank you to @Pharmavoice and @Meagan Parrish for the opportunity to contribute! 🔗 https://lnkd.in/gAyq_fRG #FDA #Biotech #LifeSciences #Innovation

Tonix Pharmaceuticals CEO, Dr. Seth Lederman, will present and host investor meetings at two upcoming conferences in San Francisco. On Sunday, January 11 Tonix will present at the Sachs Associates 9th Annual Neuroscience Innovation Forum at 11:55 a.m. PT, and participate in the “Innovation in Neuropsychiatric Drug Development” panel at 1:15 p.m. PT. Dr. Lederman will also present at Biotech Showcase 2026 on Tuesday, January 13 at 11:00 a.m. PT. Read more here: https://bit.ly/49taPmZ #Tonix #TNXP #Biotech #Neuroscience #InvestorConferences

We’re announcing an update on our TNX-4800 program for Lyme disease. Due to the high unmet need and the fact that over 70 million Americans live, work and vacation in areas of large tick populations, we are exploring new development options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field study. Read more here: https://bit.ly/4avTb4d

Tonix Pharmaceuticals CEO Dr. Seth Lederman shares his thoughts in a new DC Journal piece on why pain is still a vital sign and why chronic pain patients deserve access to science driven, non-opioid solutions. Read more here: https://lnkd.in/eFnFtuyS #TonixPharmaceuticals #PainManagement #ChronicPain #NonOpioid #LifeSciences

Tonix Pharmaceuticals has just licensed a novel compound from Rutgers University that is designed to treat chronic neuropathic pain. TNX-4900 advances research into non-opioid solutions for chronic pain. The new program reinforces Tonix’s commitment to investigating potential new therapies for patients suffering from debilitating pain conditions. Read more here: https://bit.ly/44xsMPI

We are pleased to announce the appointment of Irina Ishak as General Counsel. Ms. Ishak brings more than 25 years of corporate and commercial legal experience advising public and private life sciences companies, as well as sector investors. Ms. Ishak will play a key role in guiding our legal strategy as we work to provide innovative medicines to patients with unmet medical needs. Read more here: https://bit.ly/4pqC7B8

We’re proud to report the FDA has cleared our IND for TNX-102 SL in Major Depressive Disorder. Clinical trials in MDD are scheduled to start in 2026. This milestone reflects our commitment to studying TNX-102 SL in new indications where there is significant unmet medical need. Read more here: https://bit.ly/4polmpL

Today we launched the first therapy approved in the US for fibromyalgia in 15 years. We are proud to provide patients a new therapeutic option. Read more here: https://bit.ly/48fcayl